Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Gritstone Bio Inc (GRTS)

Gritstone Bio Inc (GRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,697
  • Shares Outstanding, K 98,066
  • Annual Sales, $ 16,340 K
  • Annual Income, $ -138,490 K
  • 60-Month Beta 0.38
  • Price/Sales 4.43
  • Price/Cash Flow N/A
  • Price/Book 1.55
Trade GRTS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.20
  • Most Recent Earnings $-0.26 on 03/05/24
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 76.12% ( -98.51%)
  • Historical Volatility 217.32%
  • IV Percentile 2%
  • IV Rank 14.08%
  • IV High 362.71% on 03/28/24
  • IV Low 29.15% on 02/07/24
  • Put/Call Vol Ratio 1.68
  • Today's Volume 1,082
  • Volume Avg (30-Day) 4,617
  • Put/Call OI Ratio 2.34
  • Today's Open Interest 85,660
  • Open Int (30-Day) 68,901

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.32
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.38
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6716 +10.96%
on 04/16/24
2.9400 -74.65%
on 03/28/24
-1.6348 (-68.69%)
since 03/15/24
3-Month
0.6716 +10.96%
on 04/16/24
3.1350 -76.23%
on 01/26/24
-2.1548 (-74.30%)
since 01/17/24
52-Week
0.6716 +10.96%
on 04/16/24
3.3300 -77.62%
on 10/10/23
-2.1048 (-73.85%)
since 04/17/23

Most Recent Stories

More News
Stocks Tread Water Before the Open as Investors Await Key U.S. GDP Data, Nike Earnings on Tap

December S&P 500 futures (ESZ23) are up +0.04%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.05% this morning as market participants geared up for a flurry of U.S. economic data while also...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
NEE : 63.79 (+3.39%)
ZION : 39.36 (-0.35%)
PAYX : 119.14 (-1.65%)
NKE : 94.84 (+1.55%)
ACN : 314.54 (+0.19%)
JBL : 129.65 (-1.81%)
KMX : 68.53 (-1.82%)
RYA.I.DX : 21.040 (+4.11%)
MU : 116.33 (-4.47%)
PTON : 3.09 (-0.32%)
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates

Janux Therapeutics, Inc. (JANX) delivered earnings and revenue surprises of 14.29% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

JANX : 47.96 (-5.12%)
GRTS : 0.7452 (-3.46%)
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 17.02% and 4.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

NTLA : 21.50 (-1.42%)
GRTS : 0.7452 (-3.46%)
Gritstone bio Inc. (GRTS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GRTS : 0.7452 (-3.46%)
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 3.23% and 38.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

GRTS : 0.7452 (-3.46%)
CRBU : 3.91 (-2.49%)
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

VYGR : 7.74 (-3.01%)
GRTS : 0.7452 (-3.46%)
Gritstone bio Inc. (GRTS) Reports Q3 Loss, Lags Revenue Estimates

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 10.26% and 22.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

GRTS : 0.7452 (-3.46%)
MNKD : 4.10 (+1.23%)
Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors

-- Expert in virology, immunology and vaccine development’s appointment effective August 12 --...

GRTS : 0.7452 (-3.46%)
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Tops Revenue Estimates

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 15% and 117.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

GRTS : 0.7452 (-3.46%)
RAPT : 8.04 (-1.11%)
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.7452 (-3.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict...

See More

Key Turning Points

3rd Resistance Point 0.8400
2nd Resistance Point 0.8175
1st Resistance Point 0.7813
Last Price 0.7452
1st Support Level 0.7226
2nd Support Level 0.7001
3rd Support Level 0.6639

See More

52-Week High 3.3300
Fibonacci 61.8% 2.3145
Fibonacci 50% 2.0008
Fibonacci 38.2% 1.6871
Last Price 0.7452
52-Week Low 0.6716

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar